Zimmer Biomet (NYSE:ZBH – Get Free Report) had its target price lifted by Sanford C. Bernstein from $93.00 to $107.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a “market perform” rating on the medical equipment provider’s stock. Sanford C. Bernstein‘s price target would indicate a potential upside of 0.26% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Weiss Ratings raised shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Canaccord Genuity Group upped their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Argus restated a “buy” rating and issued a $125.00 target price on shares of Zimmer Biomet in a report on Thursday, October 22nd. Finally, BMO Capital Markets restated a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Seven analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $107.63.
Get Our Latest Analysis on ZBH
Zimmer Biomet Trading Down 3.1%
NYSE:ZBH traded down $3.43 on Thursday, reaching $106.72. The company’s stock had a trading volume of 1,277,847 shares, compared to its average volume of 2,253,712. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $112.54. The stock has a 50 day moving average price of $94.90 and a 200 day moving average price of $91.89. The firm has a market cap of $20.36 billion, a price-to-earnings ratio of 25.94, a price-to-earnings-growth ratio of 2.33 and a beta of 0.50. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2.04 billion. During the same quarter last year, the company posted $1.90 EPS. The firm’s revenue was up 3.1% compared to the same quarter last year. On average, equities analysts anticipate that Zimmer Biomet will post 8.54 EPS for the current fiscal year.
Insider Activity
In related news, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by corporate insiders.
Institutional Trading of Zimmer Biomet
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth $1,344,282,000. State Street Corp lifted its holdings in shares of Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after purchasing an additional 52,044 shares during the last quarter. Primecap Management Co. CA purchased a new stake in shares of Zimmer Biomet during the second quarter valued at $328,578,000. Dimensional Fund Advisors LP boosted its position in shares of Zimmer Biomet by 1.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after purchasing an additional 24,208 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $187,480,000. 88.89% of the stock is currently owned by institutional investors.
Zimmer Biomet News Summary
Here are the key news stories impacting Zimmer Biomet this week:
- Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, and adjusted diluted EPS of $1.90 beat analysts’ expectations. The company also raised its full-year 2026 outlook. Strong hip and S.E.T. sales helped offset softness in knees. Zimmer Biomet Announces Third Quarter 2026 Financial Results Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
- Positive Sentiment: Wells Fargo raised its price target to $113 from $103, while keeping an “equal weight” rating. Wells Fargo stock recommendations
- Neutral Sentiment: Management said it does not see a slowdown in orthopedic procedures, offering reassurance about underlying demand. Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
- Negative Sentiment: Adjusted EPS was unchanged from a year earlier, while reported diluted EPS fell 13.8% to $1.00. Knee-market weakness and margin pressure remain concerns despite growth in other product categories. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.
The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.
Further Reading
- Five stocks we like better than Zimmer Biomet
- South Korea’s Chip Exports Are Soaring—So Why Is This ETF Down 20%?
- Uber’s Profit Drop: A Speed Bump or Structural Shift?
- Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What’s Still Missing?
- The Fed Is Split on Rates—Why These 2 Treasury ETFs Could Have an Edge
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
